• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Respiratory Virus Season 2023-2024 is Shaping Up to be a Transitional One: Expert Interview

Commentary
Video

Immunization Awareness Month

Respiratory virus season 2023-2024 will likely be a "transition year," according to family physician Chuck Vega, MD and ID specialist Bill Schaffner, MD. Here's why.

"You come for the facts, but you stay for the speculation," commented family physician Chuck Vega, MD, referring to a recent interview with Patient Care on the 2023-2024 respiratory virus season, now about 1 month away.

He joined infectious disease specialist Bill Schaffner, MD, to offer opinions, persepctives, and yes, speculation, about what primary care clinician's might expect this fall and into the winter of 2024.

Schaffner says this is going to be a "transition year," with virus circulation potentially approaching pre-pandemic timing and with the first-ever respiratory syncytial virus for adults ready to deliver and a new COVID-19 monovalent booster scheduled to arrive in September. More in the conversation below.



William Schaffner, MD, is professor of infectious disease and preventive medicine in the Department of Health Policy, and professor of medicine in the Division of Infectious Diseases at Vanderbilt University School of Medicine in Nashville, TN. Twitter: @NFIDvaccines

Charles Vega, MD is Health Sciences Clinical Professor and Associate Dean for Diversity and Inclusion at the UC Irvine School of Medicine where he also serves as executive director for the UC Irvine Program in Medical Education for the Latino Community.



For other conversations in our series with Drs William Schaffner and Chuck Vega:

Keep the Vaccination Conversation Going—and Cheerlead, Too

3 Dangerous Respiratory Viruses, 3 Robust Vaccines, 3 Shots at Broad Protection This Year

The Respiratory Syncytial Virus Vaccine for Older Adults: The New Shot on the Block

The State of Vaccine Willingness in the US: A Primary Care and an Infectious Disease Physician Discuss


Related Content
© 2024 MJH Life Sciences

All rights reserved.